Global Biobanking market is expected to grow at a CAGR of 7.2% during 2021-2027. A biobank is a biorepository that is used to store biological samples of human to be used in research. Most of the bio-banked samples are used by research groups for the development of new tests and effective treatment of cancer. The growth of the market has been propelled by cohesive government policies and funding from government and private ventures in biobanks. Large biobanks were supported by government and charitable organizations while private funding maintains the pharmaceutical biobanks. For an instance, in the US, Cancer Human Biobank, Bethesda, MD (the caHUB) was developed and supported by the National Cancer Institute (NCI) for the preservation of high-quality human cancer tissue samples for medical research.
Get Free Sample Copy @ https://www.omrglobal.com/request-sample/biobanking-market
Moreover, the other factors contributing to the growth of the market include development in genomic research and other research programs such as clinical proteomics tumor analysis consortium. Additionally, increasing demand for cost-effective drug discovery, and advancement in biobanking are contributing significantly into the growth of the market. However, issues regarding biospecimen sample procurement and strict regulatory framework may affect the growth of the global biobanking market.
Browse for Full Report Description@ https://www.omrglobal.com/industry-reports/biobanking-market
Geographically, the global biobanking market has been divided into North America, Europe, Asia Pacific and Rest of the World. North America has been predicted to dominate the global bio banking market owing to increasing research in cell and gene therapy, and regenerative medicine. The companies contributing to the growth of global biobanking are Abbott Laboratories, Bayer Schering Pharma AG, Cancer genetics, Eli Lilly and Company, GlaxoSmithKline, Johnson & Johnson Ltd., Merck & Company, Inc., Novartis AG, and Pfizer Inc. Majority of the biobanking market players have focus on various strategies such as acquisition or entering into strategic alliance with other major players to stay competitive and enhance their presence. Recently in March, 2017, UK biobank has taken an initiative with GSK and the Regeneron Genetics Center (RGC). Such strategies provides valuable insights to the researchers supporting the advancements in the development of new medicines for life threatening diseases.
MARKET SEGMENTATION
GLOBAL BIOBANKING MARKET BY SAMPLE TYPE
- BLOOD PRODUCTS
- HUMAN TISSUES
- NUCLEIC ACID
- BIOLOGICAL FLUID
- HUMAN WASTE PRODUCT
GLOBAL BIOBANKING MARKET BY APPLICATION
- CLINICAL RESEARCH
- REGENERATIVE MEDICINE
COMPETITIVE LANDSCAPE
- KEY STRATEGIES
- KEY COMPANY ANALYSIS
REGIONAL ANALYSIS
NORTH AMERICA
- UNITED STATES
- CANADA
EUROPE
- UNITED KINGDOM
- FRANCE
- GERMANY
- ITALY
- SPAIN
- REST OF EUROPE
ASIA PACIFIC
- INDIA
- CHINA
- JAPAN
REST OF THE WORLD
COMPANY PROFILES
- ABBOTT LABORATORIES INC
- AFFYMETRIX, INC
- ASTERAND PLC
- ASTRAZENECA LTD
- BAYER SCHERING PHARMA AG
- BIOCHAIN-GENOMICS
- BIOSTORAGE TECHNOLOGIES, INC.
- BOEHRINGER INGELHEIM GMBH
- BRISTOL-MYERS SQUIBB CO
- CANCER GENETICS
(This release has been published on OMR Industry Journal. OMR Industry Journal is not responsible for any content included in this release.)
